Neurogene Inc.
NGNE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404644
No open-market purchases or sales by Neurogene Inc. insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:16 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2026 | Mar 24, 2025 | Mar 18, 2024 | – | Mar 1, 2022 |
| Revenue | $0 | $925.0K | – | – | – |
| Operating expenses | $103.3M | $83.5M | $55.6M | $59.1M | – |
| Research and development | $75.0M | $60.9M | $44.4M | $41.1M | $39.2M |
| Selling, general and administrative | $28.3M | $22.6M | $11.2M | $18.0M | $21.5M |
| Operating income | -$103.3M | -$82.6M | -$55.6M | -$59.1M | -$60.7M |
| Interest expense | – | – | $12.0K | – | – |
| Income tax | $0 | – | – | – | – |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$57.6M | -$60.7M |
| EPS, basic | $-4.24 | $-4.28 | – | $-1.04 | $-1.10 |
| EPS, diluted | $-4.24 | $-4.28 | – | $-1.04 | $-1.10 |
| Weighted shares, basic | 21.3M | 17.6M | – | 55.2M | 55.0M |
| Weighted shares, diluted | 21.3M | 17.6M | – | 55.2M | 55.0M |
| Margins and growth | |||||
| Operating margin | – | -8930.3% | – | – | – |
| Net margin | – | -8123.7% | – | – | – |
| Revenue growth, year over year | −100.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2026 | Mar 24, 2025 | Mar 18, 2024 | – | Mar 1, 2022 |
| Cash and equivalents | $103.8M | $136.6M | $148.2M | $37.9M | $142.5M |
| Short-term investments | $165.2M | $175.8M | $48.9M | $58.5M | – |
| Total current assets | $271.8M | $315.9M | $200.3M | $99.1M | $144.0M |
| Property, plant and equipment | $12.8M | $15.4M | $17.2M | – | – |
| Intangible assets | – | – | – | $0 | $128.0K |
| Total assets | $288.6M | $335.7M | $222.6M | $115.9M | $163.3M |
| Accounts payable | $1.95M | $1.34M | $2.60M | – | – |
| Total current liabilities | $16.4M | $15.2M | $23.0M | $11.1M | $8.64M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $21.6M | $20.4M |
| Shareholders' equity | $264.9M | $310.4M | $186.0M | $94.3M | $142.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2026 | Mar 24, 2025 | Mar 18, 2024 | – | Mar 1, 2022 |
| Operating cash flow | -$77.2M | -$70.6M | -$51.4M | -$45.6M | -$47.6M |
| Capital expenditures | $1.18M | $808.0K | $321.0K | $1.11M | $3.26M |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$46.7M | -$50.8M |
| Depreciation and amortization | $3.04M | $3.19M | $3.26M | $1.56M | $1.31M |
| Stock-based compensation | $14.2M | $8.32M | $1.42M | $8.83M | $11.6M |
| Investing cash flow | $14.0M | -$125.3M | $25.6M | -$59.1M | -$3.26M |
| Financing cash flow | $30.4M | $184.1M | $92.5M | $161.0K | $732.0K |
| Net change in cash | -$32.7M | -$11.8M | $66.7M | -$104.6M | -$50.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 899.5% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 20.7M | +33.6% | SEC |
| Aug 7, 2026 | 20.0M | +40.2% | SEC |
| May 8, 2026 | 15.8M | +10.8% | SEC |
| Mar 18, 2026 | 15.6M | +4.3% | SEC |
| Nov 11, 2025 | 15.5M | +4.3% | SEC |
| Aug 6, 2025 | 14.3M | +9.8% | SEC |
| May 5, 2025 | 14.3M | +9.9% | SEC |
| Mar 18, 2025 | 14.9M | +16.2% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-5 in Q3 2023 and 1-for-4 in Q4 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.